EX-99.3 5 ex99_3.htm EXHIBIT 99.3 FACT SHEET ex99_3.htm  
 

PAGE 1
Investor Fact Sheet
Ticker Symbol: CEMI
www.chembio.com

Business Summary & Investment Highlights
 
Chembio Diagnostics, Inc., (Chembio), through its wholly-owned subsidiary Chembio Diagnostic Systems, Inc. develops, manufactures, licenses and markets point-of-care testing (POCT) products. Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create significant new revenue streams that will add to Chembio’s core business of rapid HIV tests.
 
 
·  
Three Consecutive Years of Profitability and Revenue Growth
 
 
·  
Strategy is to create core business of public health and women’s health products to be complemented by OEM and selected out-licensing opportunities.
 
 
·  
Robust pipeline of POCT products for infectious diseases based on Chembio’s patented DPP® technology.
 
 
·  
Products developed on DPP® platform include oral fluid HIV test anticipated to be reviewed by FDA during 2012.   Unique Syphilis test will be undergoing US FDA regulatory evaluations/submission in 2012.  Several other products and collaborations in pipeline.
 
 
·  
Unique opportunity to participate in nascent U.S. market for OTC HIV tests with multiple product offerings.
 
 
·  
Five DPP® products approved in Brazil during 2010-11 are anticipated to generate at least $9MM in 2012 revenues as compared with $4.5MM in 2011.
 
 
Selected Financial Information
 
Stock Information
Ticker Symbol: CEMI
Price 04/30/2012 $0.490
52 Week High $0.57
52 Week Low $0.210
Outstanding Shares (MM) 63.9
Market Capitalization (MM) $31.3
Fully Diluted (FD) Shares 69.7
Management Holding-FD 12.5
Average Daily Vol. (3 Mos) 32,500


Major Beneficial Holders Beneficial Shares Owned (MM)
Lawrence Siebert 7.3
Alere North America, Inc. 5.4

 
 
 
 


     
Balance Sheet Data ($000s)
Mar’12
Dec ‘11
Cash
$2,954
$ 3,011
Accts. Receivable
3,617
2,998
Inventories
2,707
2,300
Other Current Assets
755
682
Total Current Assets
10,033
8,991
Net Fixed Assets
1,119
1,062
Other Assets
5,208
5,432
Total Assets
16,360
15,486
Total Current Liab.
3,311
2,858
Total Other Liab.
121
133
Total Liabilities
3,254
2,991
Total Equity
13,106
12,495
Total Liabilities & Stockholders’ Equity
$16,360
$15,486
     

Selected Comparative Historical Financial Data

 
For the Quarter Ended /               For the Year Ended
  
$(000s)
 
Q1’12
 
Q1’11
 
2011
 
 2010
  2009
 2008
  
Total Revenues
$6,653
$3,635
$19,388
 $ 16,705
 $13,834
 $11,050
  
Cost of sales
3,320
1,709
    9,998
      8,604
      7,974
      7,198
  
Gross Profit
3,333
1,926
    9,390
     8,101
      5,860
      3,852
  
 
50.1%
53%
48.4%
     48.5%
42.4%
 34.9%
  
R&D Expense
1,379
1,290
    4,878
      2,586
      2,884
      2,605
  
SG&A Expense
1,234
775
    3,424
      2,941
      2,659
      3,317
  
Operating Income (Loss)
720
(139)
   1,088
      2,574
         317
     (2,071)
  
Other Inc. (Expense)
(1)
(3)
(12)
        (15)
           (8)
         122
  
Net Income (Loss) -PreTax
719
(142)
  1,076
       2,559
         309
     (1,949)
  
Inc. Tax(Ben.) Prov.
286
-
 (5,133)
-
-
-
  
Net Income (Loss)
$433
($142)
$6,209
        
Net Income (Loss) - per Share
$0.01
$0.00
$0.10
 $    0.04
 $   0.00
$    (0.03)
  
Wt. Avg. No. Shares (Millions)
63.475
62.285
63.328
   62.103
    61.946
    61.267
  
Working capital
6,899
4,532
6,134
 $  4,560
 $ 1,494
 $ 1,664
  
Total assets
16,360
7,675
15,486
   9,086
   6,315
 5,915
  
Total liabilities
3,254
1,939
2,991
  3,277
      3,227
   3,338
  
Equity
13,105
5,736
12,495
5,809
   3,088
   2,577
  


 Chembio Diagnostics, Inc.
Investor Relations
 Company Contact
 3661 Horseblock Road
Lippert-Heilshorn & Associates
Susan Norcott
 Medford, NY 11763
Anne-Marie Fields, Vice President
 631-924-1135 x125
 Ph. 631-924-1135
(212) 838-3777
 snorcott@chembio.com
 Fax 631-924-2065
AFields@lhai.com
  
 www.chembio.com
    
 

PAGE 2 – See Graphics

DPP® Technology
Competitive Advantages For POC Testing

• Improved Sensitivity - enabled by more efficient binding method
• Easier Multiplexing - due to even and direct distribution of sample to multiple test lines
• Enhanced Sample Control - as result of independent sample migration path
• Clearer Results - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results

Chembio’s Dual Path Platform (DPP®) Patented in 2007  (see graphic)


Chembio’s Lateral Flow Rapid HIV Tests Marketed Exclusively in the USA by Alere North America, Inc.


Senior Management Team
Lawrence A. Siebert, Chairman & CEO, over 25 years of management and financing experience
Richard J. Larkin, CFO, over 25 years of operational and financial experience
Javan Esfandiari, SVP R&D, over 15 years of experience in development of in-vitro point-of- care products

Independent Members of Board of Directors
Katherine Davis - Former Lieutenant Governor and numerous other leadership positions for the State of Indiana; former senior executive of Cummins, Inc. (NYSE:CMI)
Dr. Barbara DeBuono – Former New York Commissioner of Health and Rhode Island Director of Health; other positions in domestic and international medical services
Dr. Peter Kissinger – Has founded and/or led 3 biotechnology and/or biomedical technology companies, including a publicly-traded NASDAQ company
Dr. Gary Meller - Broad experience in medical and information technology and pharmaceutical product development

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostic’s Inc. most recent Form 10-K and Forms 10-Q for additional information about the Company and related risks. –May 2012.